NAMPT as the primary target of KPT-9274 in AML. (A) Variable expression of NAMPT protein in AML cell lines and patient samples. (B) Expression levels in AML patient samples with common genetic aberrations (Bloodspot; The Cancer Genome Atlas AML data). (C) MV4-11 and THP-1 cells treated with KPT-9274 were assessed for NAD⁺ reduction after 24 hours of treatment (n = 3). (D) Annexin V/propidium iodide (PI) flow cytometric analysis of KPT-9274–treated cell lines MV4-11 and THP-1 after addition of 100 µM of exogenous NAD⁺. (E) Western blot analysis showing the degree of CRISPR-Cas9 knockdown (KD) of NAMPT in THP-1 cells after 120 hours of doxycycline (dox) treatment. Graph shows mitochondrial activity analysis of cell lines treated with doxycycline of CRISPR-Cas9 NAMPT knockdown THP-1 cell line using MTS (n = 3).